In both trials -- ATLAS-INH, which evaluated fitusiran in patients with inhibitors, and ATLAS-A/B, which evaluated the therapy in those without inhibitors – the number of bleeding events in patients ...

Fitusiran is a new drug that has been developed for the treatment of hemophilia and has shown promising results in clinical trials. Fitusiran is a breakthrough drug for the treatment of hemophilia A ...

Fitusiran, a novel RNAi therapy in development, has the potential to transform the treatment of hemophilia with a monthly, subcutaneous treatment for people with hemophilia A and B, with or without ...

Please provide your email address to receive an email when new articles are posted on . The subcutaneously administered small interfering RNA therapy conferred a 90.8% reduction in the annualized ...

Image of blood cells. Researchers sought to determine whether fitusiran prophylaxis would reduce the rate of bleeding events among patients with hemophilia A or B with inhibitors. The following ...

Both Phase 3 studies achieved their primary and secondary endpoints; fitusiran prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all study ...

Sanofi has revised the dosing scheme in its phase 3 assessment of RNAi drug fitusiran to reduce the risk of vascular thrombotic events in hemophilia patients. The revised scheme is intended to prevent ...

Fitusiran is an investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia A and B and rare bleeding disorders (RBD). Fitusiran is designed to prevent bleeding in ...

Please provide your email address to receive an email when new articles are posted on . Once-monthly fitusiran prophylaxis improved outcomes compared with on-demand treatment for patients with severe ...

Both Phase 3 studies achieved their primary and secondary endpoints; fitusiran prophylaxis demonstrated significant and clinically meaningful improvements in bleed protection across all hemophilia ...

A median annualized bleeding rate (ABR) of 0.0 was reported in the overall study population during fitusiran prophylaxis (80 mg monthly) Fitusiran is a novel, investigational subcutaneously ...

Two trials presented at the annual meeting of the American Society of Hematology (ASH) showed that treatment with the antithrombin inhibitor fitusiran reduced the bleeding rate in patients with severe ...